The Invisible Graveyard: Quantifying the Mortality Cost of FDA Efficacy Lag, 1962-2024

This study quantifies the cumulative mortality and morbidity costs associated with the Unitary Pre-Market Approval (UPMA) model mandated by the 1962 Kefauver-Harris Amendments. By enforcing efficacy testing prior to market entry, the current regulatory framework imposes an average "Efficacy Lag" of 8.2 years (95% CI: 4.85 years-11.5 years) post-safety verification. Using data from the Tufts Center for the Study of Drug Development (CSDD) and the WHO Global Burden of Disease (GBD) database, we estimate two distinct mortality costs: (1) Historical mortality (1962-2024): approximately 102M deaths (95% CI: 36.9M deaths-214M deaths) died waiting for approved drugs during their approval delays, representing a lower bound excluding drugs never developed due to cost barriers; (2) Future timeline shift: an additional 416M deaths (95% CI: 225M deaths-630M deaths) will eventually die because the disease eradication timeline has been pushed back by 8.2 years (95% CI: 4.85 years-11.5 years). Combined, these represent 7.94B DALYs (95% CI: 4.43B DALYs-12.1B DALYs) Disability-Adjusted Life Years when adjusted for morbidity, with a cumulative economic deadweight loss of approximately $1.19 quadrillion (95% CI: $443T-$2.41 quadrillion) (2024 USD). The societal cost of Type II Regulatory Errors (delayed access to effective therapies) exceeds the averted cost of Type I Regulatory Errors (market access for ineffective therapies) by a factor of 3.07k:1 (95% CI: 2.88k:1-3.12k:1).